comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-02 01:04:52 - browse：6

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Republicans love RFK Jr. What's that tell us about health in 2024?

hotspot

WSS

The stock market has soared this year, but will it last? Experts weigh in

Kellogg’s is going to war over Mexico’s nutrition label rules

Abortion policy in the spotlight at Republican debate

National associations that represent hospice owe an apology

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

Telehealth startups are trying to fill the menopause care vacuum

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

entertainment

Jerome Adams on the need for new antivirals for Covid

Intellia plays down concerns on accidental germline transmission

George Santos makes 1st court appearance after pleading not guilty to 13 counts

A new ‘biological computer' targets cancer while sparing healthy cells

Peter Hotez and the public health issue of online harassment

Kellogg’s is going to war over Mexico’s nutrition label rules

After affirmative action ruling, medical educators look to 'holistic review'

Health officials lay out plans to cope with respiratory virus season

Hepatitis C has a cure — but many Americans still lack access to it

FDA advisory panel to debate high blood pressure devices

entertainment

PBMs are inflating the cost of generic drugs. They must be reined in

There’s a way to spot data fakery. All journals should be using it

Stanford president’s abrupt resignation sparks debate

The stock market has soared this year, but will it last? Experts weigh in

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

knowledge

leisure time

hotspot

hotspot